PubMed · 1992 · 15 citations · 0 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyCritical Care PharmacologyPharmacodynamicsPlatelet FunctionPlatelet PhysiologyVasoactive Drug TherapyAcute Disseminated Intravascular CoagulationAntagonist PotencyPharmacological PotencyPharmacological TherapyPlatelet Aggregation InhibitionPlatelet InhibitionVasoactive Drug AdministrationVasoactive Drug Mechanisms
TCV-309 potently and specifically inhibited the diverse biological actions of PAF such as platelet aggregation, hypotension, increased vascular permeability, bronchoconstriction and death. TCV-309 did not cause hemolysis or vascular irritation. TCV-309 showed beneficial effects on experimental endotoxic shock, anaphylactic shock and disseminated intravascular coagulation.